Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

June 30, 2039

Study Completion Date

December 31, 2039

Conditions
Langerhans Cell Histiocytosis
Interventions
DRUG

Trametinib

Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.

Trial Locations (1)

76104

RECRUITING

Cook Children's Health Care System, Fort Worth

All Listed Sponsors
lead

Cook Children's Health Care System

OTHER